PMS-601, a new platelet-activating factor receptor antagonist that inhibits human immunodeficiency virus replication and potentiates zidovudine activity in macrophages

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 11, 2000, Pages 3150-3154

  Martin, M ^a   Serradji, N ^a   Dereuddre Bosquet, N ^a   Le Pavec, G ^a   Fichet, G ^a   Lamouri, A ^a   Heymans, F ^a   Godfroid, J J ^a   Clayette, P ^a   Dormont, D ^a  

^a INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BIS(3',4',5' TRIMETHOXYBENZOYL) 2 (N,N DIETHYLAMINOCARBONYLOXYMETHYL)PIPERAZINE; BETA CHEMOKINE; CYTOKINE; INDINAVIR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PMS 601; RANTES; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZIDOVUDINE;

ADJUVANT CHEMOTHERAPY; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; VIRUS REPLICATION;

ANTI-HIV AGENTS; DRUG SYNERGISM; HIV; HUMANS; MACROPHAGES; PIPERAZINES; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED; VIRUS REPLICATION; ZIDOVUDINE;

EID: 0033734832     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.11.3150-3154.2000     Document Type: Article

References (32)

1. A new classification for HIV-1
2. Possible involvement of HIV in neuropsychiatric episode in a patient seronegative for two (or more) years
3. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy
4. Effects of RP 55778, a tumor necrosis factor alpha synthesis inhibitor, on antiviral activity of dideoxynucleosides
5. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia
6. Lack of interleukin-10 expression in monocyte-derived macrophages in response to in vitro infection by HIV type 1 isolates
7. Changes to AIDS dementia complex in the era of highly active anti-retroviral therapy
8. Platelet-activating factor (PAF) enhances tumor necrosis factor production by alveolar macrophages. Prevention by PAF receptor antagonists and lipoxygenase inhibitors
9. Theory and practice of centrifugal elutriation (CE): Factors influencing the separation of human blood cells
10. Characterization of a promonocyte clone chronically infected with HIV and inducible by 13-phorbol-12-myristate acetate
11. Human immunodeficiency virus type 1 (HIV-1) infection of the central nervous system: An evaluation of cytokines in cerebrospinal fluid
12. The role of mononuclear phagocytes in HTLV-III/LAV infection
13. Platelet-activating factor: A candidate human immunodeficiency virus type 1-induced neurotoxin
14. Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia
15. Immunocytochemical quantitation of human immunodeficiency virus in the brain: Correlations with dementia
16. Neuropathology of early HIV-1 infection
17. Inter-relationships between quinolinic acid, neuroactive kynurenines, neopterin and beta 2-microglobulin in cerebrospinal fluid and serum of HIV-1-infected patients
18. Involvement of nuclear factor-kappa B in platelet-activating factor-mediated tumor necrosis factor-alpha expression
19. Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia
20. Treatment of human monocyte-derived macrophages with a TNF-alpha synthesis inhibitor prior to HIV1 infection: Consequences on cytokine production and viral replication
21. Neurologic manifestations of AIDS
22. Anti-inflammatory effect of a PAF receptor antagonist and a new molecule with antiproteinase activity in an experimental model of acute urate crystal arthritis
23. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators
24. Microglial and astrocyte chemokines regulate monocyte migration through the blood-brain barrier in human immunodeficiency virus-1 encephalitis
25. Chemokines and receptors in HIV encephalitis
26. Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurological AIDS Research Consortium
27. Human immunodeficiency virus type 1 infection alters chemokine, beta peptide expression in human monocytes: Implications for recruitment of leukocytes into brain and lymph nodes
28. Structure-activity relationships in platelet-activating factor (PAF). 10. From PAF-antagonism to inhibition of HIV-1 replication
29. Cytokine expression in the brain during the acquired immunodeficiency syndrome
30. A platelet-activating factor antagonist, RP 55778, inhibits cytokine-dependent induction of human immunodeficiency virus expression in chronically infected promonocytic cells
31. Possible participation of intracellular platelet-activating factor in tumor necrosis factor-alpha production by rat peritoneal macrophages
32. The HIV-1 associated dementia complex: A metabolic encephalopathy fueled by viral replication in mononuclear phagocytes